Page last updated: 2024-10-31

mitoxantrone and Acute Promyelocytic Leukemia

mitoxantrone has been researched along with Acute Promyelocytic Leukemia in 72 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL)."9.11High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. ( Benner, A; del Valle y Fuentes, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Germing, U; Glasmacher, A; Götze, K; Grimminger, W; Hartmann, F; Hensel, M; Nerl, C; Petzer, A; Pralle, H; Salwender, H; Schlenk, RF; Zick, L, 2005)
"The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy."8.82Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003)
"Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin."7.76Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010)
"Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)."7.74Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008)
"Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML)."7.74Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. ( Galetta, SL; Ko, MW; McGrath, C; Porter, D; Tamhankar, MA; Volpe, NJ, 2008)
"Therapeutic advances in acute promyelocytic leukemia (APL) have transformed it into today's most curable form of leukemia."5.91Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. ( Gómez-Almaguer, D; González-Treviño, M; Jaime-Pérez, JC; Meléndez-Flores, JD; Ramos-Dávila, EM, 2023)
"The aim of our study was to evaluate the impact of oral arsenic (the realgar-indigo naturalis formula, RIF) and all-trans retinoic acid (ATRA) on coagulopathy in acute promyelocytic leukemia (APL) compared with intravenous arsenic trioxide (ATO) and ATRA during induction."5.27The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. ( Guo, ZP; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Zhu, HH, 2018)
"The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL)."5.11High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. ( Benner, A; del Valle y Fuentes, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Germing, U; Glasmacher, A; Götze, K; Grimminger, W; Hartmann, F; Hensel, M; Nerl, C; Petzer, A; Pralle, H; Salwender, H; Schlenk, RF; Zick, L, 2005)
"The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy."4.82Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003)
"In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics."3.88Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics. ( Hu, LN; Li, GQ; Lin, HQ; Shen, Q; Sun, XF; Zhang, XY; Zhou, JH, 2018)
"Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL."3.81Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. ( Adès, L; Beaumont, M; Bordessoule, D; Braun, T; Cereja, S; Chevret, S; Chomienne, C; Degos, L; Detourmignies, L; Dombret, H; Fenaux, P; Guerci, A; Lamy, T; Pigneux, A; Poiré, X; Raffoux, E; Recher, C; Spertini, O; Thomas, X; Tournilhac, O, 2015)
" We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ)."3.77Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. ( Bernardi, G; Buttari, F; Centonze, D; Cicconi, L; Garagnani, P; Hasan, SK; Hohaus, S; Lo-Coco, F; Mantovani, V; Marasco, E; Ottone, T; Sanz, MA; Voso, MT, 2011)
"Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin."3.76Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010)
"Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS)."3.75Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? ( Boggild, M; Ellis, R, 2009)
"Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)."3.74Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008)
" However, cases are emerging after mitoxantrone therapy for multiple sclerosis (MS)."3.74Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. ( Amadori, S; Borlenghi, E; Byl, JA; Cattaneo, C; Cervera, J; Esteve, J; Felix, CA; Grimwade, D; Hasan, SK; La Nasa, G; Ledda, A; Lennard, A; Libura, M; Lo-Coco, F; Mays, AN; Melillo, L; Montefusco, E; Osheroff, N; Ottone, T; Sanz, MA; Satchi, G; Sperr, WR; Stephen, C; Voso, MT, 2008)
"Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML)."3.74Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. ( Galetta, SL; Ko, MW; McGrath, C; Porter, D; Tamhankar, MA; Volpe, NJ, 2008)
"We report two new cases of mitoxantrone-related leukemia occurring in two patients with multiple sclerosis (MS), 14 and 18 months after the last infusion of the drug."3.74Mitoxantrone-related acute leukemia in two MS patients. ( Gille, M; Goffette, S; Pielen, A; Sindic, CJ; Van Pesch, V, 2008)
"Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons."3.73DNA topoisomerase II in therapy-related acute promyelocytic leukemia. ( Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL, 2005)
"Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS)."3.73Acute myeloid leukaemia induced by mitoxantrone: case report. ( Arruda, WO; de Oliveira, Mde S; Montú, MB; Ramina, R, 2005)
" Remission induction therapy was performed for a 46-year-old Japanese man with acute promyelocytic leukemia using ATRA (45 mg/m2), enocitabine (170 mg/m2, 5 days), and mitoxantrone (4 mg/m2, 3 days)."3.73[Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid]. ( Amaya, N; Arai, H; Lee, JD; Taga, M; Ueda, T; Yamauchi, T, 2005)
"We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia."3.72MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. ( Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S, 2003)
"To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed."2.73Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. ( Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M, 2007)
"Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction."2.72The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. ( Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS, 2006)
"Molecular relapse was defined as reappearance of RT-PCR-positivity for the PML/RARalpha fusion (sensitivity 10(-4)) in 2 successive marrow samples collected during postconsolidation monitoring."2.69Therapy of molecular relapse in acute promyelocytic leukemia. ( Avvisati, G; Biondi, A; Carlo-Stella, C; Diverio, D; Lo Coco, F; Mandelli, F; Martino, B; Meloni, G; Petti, MC; Pogliani, EM; Rossi, G; Selleri, C; Specchia, G, 1999)
"Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached > or = 10 x 10(3)/microliters."2.67All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. ( Cortes, JE; Estey, E; Hirsh-Ginsberg, C; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Robertson, LE; Stass, S, 1994)
"Of 40 patients with AML M3 or M3 v complete remission was attained in 62."2.67Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. ( Becher, R; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Jürgensen, C; Löffler, H; Ludwig, WD; Noak, J; Thiel, E, 1993)
"Therapeutic advances in acute promyelocytic leukemia (APL) have transformed it into today's most curable form of leukemia."1.91Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. ( Gómez-Almaguer, D; González-Treviño, M; Jaime-Pérez, JC; Meléndez-Flores, JD; Ramos-Dávila, EM, 2023)
"This proadifen-MTX synergism was also mediated by the inhibition of various cellular proteins engaged in apoptosis, including Mc-1, Bcl-xL, survivin and activation of procaspase-3."1.42Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells. ( Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J, 2015)
"All-trans retinoic acid (ATRA) has made acute promyelocytic leukemia (APL) a very curable disease also in patients aged >60 years; however, there are only few case reports in very elderly APL patients."1.42Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. ( Avvisati, G; Breccia, M; Carmosino, I; Chisini, M; Cimino, G; Colafigli, G; Finsinger, P; Foà, R; Girmenia, C; Latagliata, R; Lo-Coco, F; Minotti, C; Montagna, C; Petti, MC; Romano, A; Volpicelli, P; Vozella, F, 2015)
"Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival."1.35Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008)
"We report the second case of acute promyelocytic leukemia (APL), which developed post-transplant and immunosuppressive treatment, in a 50-year-old male who had undergone a renal transplant."1.31Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case. ( Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C, 2001)
"Mucormycosis is a rare fungal infection that has been described mainly in oncologic and diabetic patients."1.29[Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases]. ( Cancelas, JA; Cerveró, C; García-Laraña, J; López, J; Navarro, JL; Odriozola, J; Pérez-Oteyza, J; Sánchez-Sousa, A; Sastre, JL, 1994)
"To evaluate our experience in the treatment of disseminated intravascular coagulation (DIC) associated to AML-M3 with substitution therapy with or without heparin."1.29[Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases]. ( Batlle, J; López Fernández, MF; Rodríguez Gómez, M, 1993)
"This paper describes two cases of acute promyelocytic leukemia diagnosed during the second trimester of pregnancy and the most suitable approach to the management of this situation is analyzed."1.29Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. ( Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG, 1995)
"We report a case of an acute promyelocytic leukemia patient who showed remarkable thrombopoiesis prior to granulopoiesis by human macrophage colony-stimulating factor (hM-CSF) treatment after chemotherapy."1.28[A case report of an acute promyelocytic leukemia patient showing remarkable thrombopoiesis prior to granulopoiesis by hM-CSF treatment after chemotherapy]. ( Akiyoshi, T; Hisano, S; Ishibashi, M; Kimura, N; Morioka, E; Okumura, M; Suzumiya, J; Uchida, T, 1992)

Research

Studies (72)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's24 (33.33)18.2507
2000's28 (38.89)29.6817
2010's19 (26.39)24.3611
2020's1 (1.39)2.80

Authors

AuthorsStudies
Cheng, CC1
Dong, Q1
Liu, DF1
Luo, YL1
Liu, LF1
Chen, AY1
Yu, C1
Savaraj, N1
Chou, TC1
Jaime-Pérez, JC2
Ramos-Dávila, EM1
Meléndez-Flores, JD1
González-Treviño, M1
Gómez-Almaguer, D2
Zhu, HH1
Guo, ZP1
Jia, JS1
Jiang, Q1
Jiang, H1
Huang, XJ1
Zhou, JH1
Lin, HQ1
Shen, Q1
Hu, LN1
Li, GQ1
Sun, XF1
Zhang, XY1
Franke, M1
Theurich, S1
Beyer, F1
Persigehl, T1
Ottone, T4
Hasan, SK5
Voso, MT3
Ledda, A3
Montefusco, E3
Fenu, S1
Pagoni, M1
Hubmann, M1
Lunghi, M2
Platzbecker, U1
Lo-Coco, F8
Ruben, JM1
van den Ancker, W1
Bontkes, HJ1
Westers, TM1
Hooijberg, E1
Ossenkoppele, GJ1
de Gruijl, TD1
van de Loosdrecht, AA1
Sanz, MA7
Iacoboni, G1
Montesinos, P1
Iland, HJ1
Wei, A1
Seymour, JF1
Finsinger, P1
Breccia, M2
Minotti, C1
Carmosino, I2
Girmenia, C1
Chisini, M1
Volpicelli, P1
Vozella, F1
Romano, A1
Montagna, C1
Colafigli, G1
Cimino, G3
Avvisati, G6
Petti, MC5
Foà, R1
Latagliata, R2
Braun, T1
Cereja, S1
Chevret, S1
Raffoux, E1
Beaumont, M1
Detourmignies, L1
Pigneux, A2
Thomas, X2
Bordessoule, D1
Guerci, A2
Lamy, T1
Recher, C1
Poiré, X1
Tournilhac, O1
Spertini, O1
Chomienne, C4
Degos, L3
Dombret, H2
Adès, L2
Fenaux, P4
Hiľovská, L1
Jendželovský, R1
Jendželovská, Z1
Kovaľ, J1
Fedoročko, P1
González-Leal, XJ1
Pinzón-Uresti, MA1
Gómez-De León, A1
Cantú-Rodríguez, OG1
Gutiérrez-Aguirre, H1
Roengvoraphoj, M1
Yan, S1
Lansigan, F1
Chapman, MS1
Danilov, AV1
Tang, YL1
Chia, WK1
Yap, EC1
Julia, MI1
Leong, CF1
Salwati, S1
Wong, CL1
Mays, AN3
La Nasa, G2
Cattaneo, C2
Borlenghi, E2
Melillo, L1
Cervera, J1
Stephen, C1
Satchi, G1
Lennard, A1
Libura, M1
Byl, JA2
Osheroff, N3
Amadori, S3
Felix, CA3
Sperr, WR1
Esteve, J3
Grimwade, D4
Bosca, I1
Pascual, AM1
Casanova, B1
Coret, F1
Ko, MW1
Tamhankar, MA1
Volpe, NJ1
Porter, D1
McGrath, C1
Galetta, SL1
Pielen, A1
Goffette, S1
Van Pesch, V1
Gille, M1
Sindic, CJ1
Ellis, R1
Boggild, M1
Ammatuna, E1
Pacilli, M1
Divona, M1
Ardiri, D1
Centonze, D2
Betancourt-García, RD1
Castro, J1
Fernández, AC1
López-Enríquez, A1
Fradera, J1
Pacheco, E1
Xiao, Y2
Wiemels, JL3
Saravanamuttu, K1
Peniket, A1
Corser, R1
Chang, C1
Hoyle, C1
Parker, AN1
Solomon, E2
Schlenk, RF2
Mitra, ME1
Bernasconi, P1
Di Raimondo, F1
Stanghellini, MT1
Marco, P1
Döhner, H2
Buttari, F1
Hohaus, S1
Marasco, E1
Mantovani, V1
Garagnani, P1
Cicconi, L1
Bernardi, G1
Taube, F1
Stölzel, F1
Thiede, C1
Ehninger, G1
Laniado, M1
Schaich, M1
Mikusová, V1
Tichý, A1
Rezáčová, M1
Vávrová, J1
Lengfelder, E2
Hanfstein, B1
Haferlach, C1
Braess, J1
Krug, U1
Spiekermann, K1
Haferlach, T2
Kreuzer, KA1
Serve, H1
Horst, HA1
Schnittger, S1
Aul, C1
Schultheis, B1
Erben, P1
Schneider, S1
Müller-Tidow, C1
Wörmann, B1
Berdel, WE1
Sauerland, C1
Heinecke, A1
Hehlmann, R2
Hofmann, WK1
Hiddemann, W2
Büchner, T1
Almici, C1
Motta, M1
Rossi, G2
Kröger, N1
Damon, L1
Zander, AR1
Wandt, H1
Derigs, G1
Ferrante, P1
Demirer, T1
Rosti, G1
Tsujioka, T1
Wada, H1
Yamamori, S1
Otsuki, T1
Suemori, S1
Kondo, T1
Nakanishi, H1
Suetsugu, Y1
Mikami, M1
Sugihara, T1
Novoselac, AV1
Reddy, S1
Sanmugarajah, J1
Bozdağ, S1
Capan, Y1
Vural, I1
Dalkara, T1
Dogan, AL1
Guc, D1
Hincal, AA1
Deluca, PP1
Mistry, AR1
Whitmarsh, RJ1
Mason, A1
Reiter, A1
Cassinat, B1
Parry, A1
Walz, C1
Segal, MR1
Blair, IA1
Peniket, AJ1
Lafage-Pochitaloff, M1
Cross, NC1
Germing, U1
Hartmann, F1
Glasmacher, A1
Fischer, JT1
del Valle y Fuentes, F1
Götze, K1
Pralle, H1
Nerl, C1
Salwender, H1
Grimminger, W1
Petzer, A1
Hensel, M1
Benner, A1
Zick, L1
Döhner, K1
Fröhling, S1
Arruda, WO1
Montú, MB1
de Oliveira, Mde S1
Ramina, R1
Yamauchi, T1
Arai, H1
Taga, M1
Amaya, N1
Lee, JD1
Ueda, T1
Lee, S1
Kim, YJ1
Eom, KS1
Min, CK1
Kim, HJ1
Cho, SG1
Lee, JW1
Min, WS1
Kim, CC1
Caocci, G1
Spinicci, G1
Cocco, E1
Mamusa, E1
Minni, A1
Testi, A1
Iorio, N1
Mandelli, F5
Escoda, L1
Martín, G2
Rubio, V1
Díaz-Mediavilla, J2
González, M3
Rivas, C1
Alvarez, C1
González San Miguel, JD1
Brunet, S1
Tomás, JF1
Tormo, M1
Sayas, MJ1
Sánchez Godoy, P1
Colomer, D2
Bolufer, P2
Klein, SK1
Biemond, BJ1
van Oers, MH1
Snijder, S1
Mellink, CH1
van der Lelie, H1
Ramkumar, B1
Chadha, MK1
Barcos, M1
Sait, SN1
Heyman, MR1
Baer, MR1
Sastre, JL1
Pérez-Oteyza, J1
López, J1
Cerveró, C1
Sánchez-Sousa, A1
García-Laraña, J1
Cancelas, JA1
Odriozola, J1
Navarro, JL1
Todisco, E1
Testi, AM1
Moleti, ML1
Cedrone, M1
Mancini, F1
Harker, WG1
Slade, DL1
Parr, RL1
Feldhoff, PW1
Sullivan, DM1
Holguin, MH1
Chastang, C1
Castaigne, S1
Sanz, M1
Link, H2
Löwenberg, B1
Fey, M1
Archim-Baud, E1
Azuno, Y1
Kaku, K1
Fujita, N1
Okubo, M1
Kaneko, T1
Matsumoto, N1
Cai, S1
Chen, J1
Ye, S1
Yu, F1
Dreosti, LM1
Bezwoda, W1
Gunter, K1
Simon, M1
Haase, D2
Hild, F1
Rodríguez Gómez, M1
López Fernández, MF1
Batlle, J1
Cortes, JE1
Kantarjian, H1
O'Brien, S1
Robertson, LE1
Koller, C1
Hirsh-Ginsberg, C1
Stass, S1
Keating, M1
Estey, E1
Gassmann, W1
Löffler, H1
Jürgensen, C1
Noak, J1
Ludwig, WD1
Thiel, E1
Fonatsch, C1
Becher, R1
Requena, A1
Velasco, JG1
Pinilla, J1
Gonzalez-Gonzalez, A1
Tobita, T1
Shinjyo, K1
Yanagi, M1
Takeshita, A1
Ohnishi, K1
Ohno, R2
Meloni, G2
Diverio, D2
Vignetti, M1
Capria, S1
Lo Coco, F3
Vicari, AM1
Ciceri, F1
Folli, F1
Lanzi, R1
Colombo, B1
Comi, G1
Camba, L1
Castagnola, C1
Corso, A1
Tajana, M1
Zappasodi, P1
Dabusti, M1
Lazzarino, M1
Bernasconi, C2
Batlle, M1
Fernández-Avilés, F1
Ribera, JM2
Millá, F1
Granada, I1
Gómez Espuch, J1
Navarro, JT1
Feliu, E1
Gutiérrez, NC1
García, JL1
Chillón, C1
Muntión, S1
Hernández, JM1
Sousa, AB1
Fernandes, JP1
Ferreira, G1
Bernardo, M1
Conduto, A1
Costa, I1
Cruz, E1
Gonçalves, AJ1
Monteiro, A1
Nunes, O1
Ribeiro, P1
Rodrigues, AS1
Sousa, M1
Veiga, J1
Gouveia, J1
Pogliani, EM1
Biondi, A1
Carlo-Stella, C1
Selleri, C1
Martino, B1
Specchia, G2
Cordonnier, C1
Gardin, C1
Vekhoff, A1
Sadoun, A1
Stamatoullas, A1
Fegueux, N1
Maloisel, F1
Cahn, JY1
Reman, O1
Gratecos, N1
Berthou, C1
Huguet, F1
Kotoucek, P1
Travade, P1
Buzyn, A1
de Revel, T1
Vilque, JP1
Naccache, P1
Rayón, C1
Barbui, T1
Fioritoni, G1
González, JD1
Liso, V2
Ferrara, F1
Rodeghiero, F1
Asou, N1
Adachi, K1
Tamura, J1
Kanamaru, A1
Kageyama, S1
Hiraoka, A1
Omoto, E1
Akiyama, H1
Puga, BL1
Cabrera, ME1
Undurraga, MS1
Etcheverry, R1
Vacarezza, R1
Ducach, G1
Toledo, H1
Storlazzi, CT1
Cuneo, A1
Surace, C1
Mestice, A1
Pannunzio, A1
Rocchi, M1
Takeuchi, N1
Nakamura, T1
Takeuchi, F1
Hashimoto, E1
Yamamura, H1
Suzumiya, J1
Morioka, E1
Kimura, N1
Ishibashi, M1
Uchida, T1
Akiyoshi, T1
Hisano, S1
Okumura, M1
Freund, M1
Wunsch-Zeddies, S1
Schäfers, M1
Wysk, J1
Seidel, I1
Hanauske, AR1
Schmoll, HJ1
Poliwoda, H1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial[NCT05497310]Phase 1/Phase 215 participants (Anticipated)Interventional2022-07-01Recruiting
Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure[NCT00015587]3,523 participants (Actual)Observational1995-04-30Completed
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ar[NCT00408278]Phase 4300 participants (Anticipated)Interventional2005-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for mitoxantrone and Acute Promyelocytic Leukemia

ArticleYear
Conventional induction and post-remission therapy in APL: have we arrived?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinic

2014
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1

    Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2014
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
    Puerto Rico health sciences journal, 2009, Volume: 28, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosome

2009
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Bone marrow transplantation, 2003, Volume: 32, Issue:12

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat

2003
Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).
    Annals of hematology, 2007, Volume: 86, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Leukemia, Promyel

2007
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
    Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Diffe

1995

Trials

11 trials available for mitoxantrone and Acute Promyelocytic Leukemia

ArticleYear
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Leukemia research, 2018, Volume: 65

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tri

2018
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
    Leukemia, 2005, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyro

2005
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
    Haematologica, 2006, Volume: 91, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression;

2006
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; C

2007
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
    Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Diffe

1995
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
    Cancer, 1994, Jun-15, Volume: 73, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug

1994
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
    Annals of hematology, 1993, Volume: 66, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Humans; Le

1993
Short-term intensive consolidation therapy after all-trans retinoic acid in acute promyelocytic leukemia.
    American journal of clinical oncology, 1999, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, P

1999
Therapy of molecular relapse in acute promyelocytic leukemia.
    Blood, 1999, Oct-01, Volume: 94, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans;

1999
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
    Blood, 2000, Aug-15, Volume: 96, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine;

2000
[Treatment of acute promyelocytic leukemia with all-trans retinoic acid and chemotherapy--multicenter trial of the Japan Adult Leukemia Study Group (JALSG)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:8

    Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2000

Other Studies

56 other studies available for mitoxantrone and Acute Promyelocytic Leukemia

ArticleYear
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
    Journal of medicinal chemistry, 1993, Dec-10, Volume: 36, Issue:25

    Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; DNA Topoisomerases, Type II; Furans; Humans

1993
Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia.
    Hematology/oncology and stem cell therapy, 2023, Jul-20, Volume: 17, Issue:1

    Topics: Anthracyclines; Doxorubicin; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Mitoxan

2023
Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
    Current medical science, 2018, Volume: 38, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine;

2018
[Pulmonary differentiation -/ATRA syndrome within the scope of therapy of acute promyelocytic leukemia (APL)].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2014, Volume: 186, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; D

2014
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.
    American journal of hematology, 2014, Volume: 89, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes

2014
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.
    Cancer immunology, immunotherapy : CII, 2014, Volume: 63, Issue:4

    Topics: Antigen Presentation; Antigens, Neoplasm; Apoptosis; Cancer Vaccines; Cell Movement; Cell-Derived Mi

2014
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
    Annals of hematology, 2015, Volume: 94, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fema

2015
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
    Cancer, 2015, Jul-15, Volume: 121, Issue:14

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemoradiother

2015
Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.
    International journal of oncology, 2015, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting,

2015
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tr

2015
Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy.
    Cutis, 2016, Volume: 98, Issue:4

    Topics: Adult; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Humans; Leukemia, Promyelocy

2016
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
    The Malaysian journal of pathology, 2016, Volume: 38, Issue:3

    Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybr

2016
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
    Blood, 2008, Oct-15, Volume: 112, Issue:8

    Topics: Adult; Antigens, Neoplasm; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; DNA; DNA Topois

2008
Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
    Neurology, 2008, Aug-05, Volume: 71, Issue:6

    Topics: Adolescent; Adult; Child; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Ag

2008
Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Journal of the neurological sciences, 2008, Oct-15, Volume: 273, Issue:1-2

    Topics: Analgesics; Female; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Middle Aged;

2008
Mitoxantrone-related acute leukemia in two MS patients.
    Acta neurologica Belgica, 2008, Volume: 108, Issue:3

    Topics: Adult; Analgesics; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; M

2008
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Multiple sclerosis (Houndmills, Basingstoke, England), 2009, Volume: 15, Issue:4

    Topics: Acute Disease; Adult; Antineoplastic Agents; Databases, Factual; Female; Humans; Leukemia, Myeloid,

2009
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:7

    Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Pro

2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
    Blood, 2010, Jan-14, Volume: 115, Issue:2

    Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Huma

2010
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
    Genes, chromosomes & cancer, 2010, Volume: 49, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes

2010
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
    Neurology, 2011, Mar-22, Volume: 76, Issue:12

    Topics: Adult; Antineoplastic Agents; DNA Repair Enzymes; Genetic Predisposition to Disease; Humans; Leukemi

2011
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
    Haematologica, 2011, Volume: 96, Issue:6

    Topics: Antineoplastic Agents; Female; Humans; Intracranial Hemorrhages; Leukemia, Promyelocytic, Acute; Mid

2011
Mitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms.
    Folia biologica, 2011, Volume: 57, Issue:5

    Topics: Acid Anhydride Hydrolases; Antineoplastic Agents; Cell Cycle Proteins; DNA Breaks, Double-Stranded;

2011
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
    Annals of hematology, 2013, Volume: 92, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxi

2013
A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Mult

2003
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
    International journal of hematology, 2003, Volume: 78, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma

2003
Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
    Leukemia, 2004, Volume: 18, Issue:9

    Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Multiple

2004
In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells.
    Journal of microencapsulation, 2004, Volume: 21, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Drug Carriers; Drug Compounding; HL-60 Cells; Humans; Leukemia

2004
DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
    The New England journal of medicine, 2005, Apr-14, Volume: 352, Issue:15

    Topics: Antineoplastic Agents; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubic

2005
Acute myeloid leukaemia induced by mitoxantrone: case report.
    Arquivos de neuro-psiquiatria, 2005, Volume: 63, Issue:2A

    Topics: Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Middle Aged

2005
[Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Heart Bloc

2005
Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.
    Leukemia, 2006, Volume: 20, Issue:12

    Topics: Adult; Female; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Mitoxantrone; Multi

2006
Late relapses in acute promyelocytic leukaemia.
    Acta haematologica, 2007, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara

2007
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
    Cancer genetics and cytogenetics, 2008, Jan-15, Volume: 180, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo

2008
Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Cancer genetics and cytogenetics, 2008, Apr-15, Volume: 182, Issue:2

    Topics: Antineoplastic Agents; Chromosomes, Human, Pair 11; Female; Humans; In Situ Hybridization, Fluoresce

2008
[Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases].
    Sangre, 1994, Volume: 39, Issue:1

    Topics: Adult; Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outco

1994
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
    Leukemia, 1995, Volume: 9, Issue:9

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes

1995
Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Cancer research, 1995, Apr-15, Volume: 55, Issue:8

    Topics: Base Sequence; Cell Line; DNA Primers; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance;

1995
Mitoxantrone and etoposide in breast milk.
    American journal of hematology, 1995, Volume: 48, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, Promyelo

1995
[Effect of prednisolon, vincristine and mitoxantrone on glucocorticoid receptor in HL-60 cell line].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1994, Volume: 25, Issue:3

    Topics: Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mitoxantro

1994
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
    Leukemia & lymphoma, 1994, Volume: 13, Issue:3-4

    Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; L

1994
[Complete remission in acute promyelocytic leukemia. The advantages of all-trans-retinoic acid compared to conventional chemotherapy].
    Deutsche medizinische Wochenschrift (1946), 1994, Aug-26, Volume: 119, Issue:34-35

    Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; D

1994
[Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases].
    Sangre, 1993, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Blood Coa

1993
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
    European journal of obstetrics, gynecology, and reproductive biology, 1995, Volume: 63, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran

1995
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
    Internal medicine (Tokyo, Japan), 1997, Volume: 36, Issue:7

    Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modalit

1997
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
    Blood, 1997, Aug-01, Volume: 90, Issue:3

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biom

1997
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis.
    Leukemia, 1998, Volume: 12, Issue:3

    Topics: Adult; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Topoisomerase

1998
Management of acute promyelocytic leukemia relapse in the ATRA era.
    Haematologica, 1998, Volume: 83, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro

1998
Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis.
    Leukemia, 1999, Volume: 13, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Idarubicin; Leuke

1999
Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
    Haematologica, 1999, Volume: 84, Issue:1

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chr

1999
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
    Leukemia, 2000, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine;

2000
[Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
    Revista medica de Chile, 2000, Volume: 128, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyt

2000
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
    Annals of hematology, 2001, Volume: 80, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1;

2001
Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells.
    Journal of biochemistry, 1992, Volume: 112, Issue:6

    Topics: Animals; Brain; Casein Kinases; Cell Division; Chromatography, Ion Exchange; Dose-Response Relations

1992
[A case report of an acute promyelocytic leukemia patient showing remarkable thrombopoiesis prior to granulopoiesis by hM-CSF treatment after chemotherapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1992, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocytes; Hematopoiesi

1992
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Annals of hematology, 1992, Volume: 64, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic,

1992